Association of treatment with metformin vs sulfonylurea with major adverse cardiovascular events among patients with diabetes and reduced kidney function

JAMA Sep 26, 2019

Roumie CL, Chipman J, Min JY, et al. - In this retrospective cohort analysis, researchers compared treatment with metformin vs sulfonylurea in terms of major adverse cardiovascular events (MACE) in patients with diabetes and reduced kidney function (n = 49,478). Participants were US veterans obtaining care within the national Veterans Health Administration. These data were linked to Medicare, Medicaid, and National Death Index data from 2001 through 2016. Hospitalization for acute myocardial infarction, stroke, transient ischemic attack, or cardiovascular death, were included in MACE. For participants who received metformin vs sulfonylurea monotherapy, the incidence of MACE was estimated to be 23.0 per 1000 person-years vs 29.2 per 1000 person-years, a difference that was statistically significant. Overall, a lower risk of MACE was reported with metformin vs sulfonylurea treatment in patients with diabetes and reduced kidney function persisting with monotherapy.
Go to Original

Sign-up to continue reading. It is free & takes less than 2 mins

  • 45 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Free & unlimited access to original articles and quizzes
  • Nonloggedinlock icon
    Secure: we never sell your data
This article is only available to members. Are you a doctor? Click here to signup for free.
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen